Yüklüyor......
Rituximab and new regimens for indolent lymphoma: a brief update from 2012 ASCO Annual Meeting
Indolent lymphoma (IL), the second most common lymphoma, remains incurable with chemotherapy alone. While R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) remains the standard frontline regimen for diffuse Large B –cell lymphoma, the optimal chemotherapy regimen for frontli...
Kaydedildi:
| Asıl Yazarlar: | , , , |
|---|---|
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
BioMed Central
2012
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3480919/ https://ncbi.nlm.nih.gov/pubmed/22913602 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1475-2867-12-38 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|